![](/img/cover-not-exists.png)
156PPalbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study
Welt, A, Welslau, M K, Lüftner, D, Deryal, M, Liersch, R, Sahlmann, J, Houet, L, Vannier, C, Marschner, N, Potthoff, KVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz100.007
Date:
May, 2019
File:
PDF, 77 KB
2019